Authors: Eter, Nicole; Krohne, Tim U.; Holz, Frank G.

Source: BioDrugs, Volume 20, Number 3, 2006 , pp. 167-179(13)

Publisher: Adis International

Abstract:

As a result of a better understanding of molecular mechanisms, a variety of new pharmacologic treatments have recently been developed for patients with age-related macular degeneration (AMD). Efficacy and tolerability have been demonstrated for drugs targeting vascular endothelial growth factor (VEGF), a key player in the pathogenesis of choroidal neovascularization. Both pegaptanib (anti-VEGF aptamer) and ranibizumab (anti-VEGF antibody fragment), applied at 4- to 6-week intervals into the vitreous, modified the natural course of the disease in phase III clinical studies. Corticosteroids with anti-angiogenic properties also represent a treatment option for wet AMD. Both intravitreal triamcinolone and anecortave acetate, administered juxtasclerally, are currently being pursued.

The combination of different treatment strategies and potential synergistic effects offers new perspectives. While photodynamic therapy (PDT) combined with intravitreal triamcinolone is already frequently applied, other combinations (e.g. anti-VEGF drugs with PDT or antifibrotic agents) appear to be attractive alternatives. Pigment epithelium-derived factor represents another potential target, as well as inhibitors of matrix-metallo-proteinases. With the advent of gene therapy, the use of small interfering RNA (siRNA) is also on the horizon.

Prophylactic measures are still limited. The combination of vitamins C and E, β-carotene, and zinc as used in the AREDS (Age-Related Eye Disease Study) reduces risk for conversion from early- to late-stage disease in patients with high-risk features, at least to some extent. Lutein and zeaxanthin dietary supplements for improvement of macular pigment density need to be investigated in future longitudinal trials.

Keywords: Age related macular degeneration; Angiogenesis inhibitors; Anti inflammatories; Antioxidants; Gene therapies; Matrix metalloproteinase inhibitors; Pigment epithelium derived factor; Research and development; Small interfering RNA; Vascular endothelial growth factor

Document Type: Research article

Affiliations: 1: Department of Ophthalmology, University of Bonn Medical Center, Bonn, Germany

Publication date: 2006-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Eter, Nicole ;  Krohne, Tim U. ;  Holz, Frank G.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers